CN115884987A - 抗gprc5d抗体的抗独特型抗体 - Google Patents

抗gprc5d抗体的抗独特型抗体 Download PDF

Info

Publication number
CN115884987A
CN115884987A CN202180049442.3A CN202180049442A CN115884987A CN 115884987 A CN115884987 A CN 115884987A CN 202180049442 A CN202180049442 A CN 202180049442A CN 115884987 A CN115884987 A CN 115884987A
Authority
CN
China
Prior art keywords
antigen
antibody
binding portion
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049442.3A
Other languages
English (en)
Chinese (zh)
Inventor
E·池
W·爱德华兹
M·胡索夫斯基
A·拉科姆
C·马丁内斯
H·M·周
J·T·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN115884987A publication Critical patent/CN115884987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180049442.3A 2020-07-17 2021-07-15 抗gprc5d抗体的抗独特型抗体 Pending CN115884987A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053286P 2020-07-17 2020-07-17
US63/053286 2020-07-17
PCT/IB2021/056418 WO2022013819A1 (en) 2020-07-17 2021-07-15 Anti-idiotypic antibodies against anti-gprc5d antibodies

Publications (1)

Publication Number Publication Date
CN115884987A true CN115884987A (zh) 2023-03-31

Family

ID=77499865

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049442.3A Pending CN115884987A (zh) 2020-07-17 2021-07-15 抗gprc5d抗体的抗独特型抗体

Country Status (7)

Country Link
US (1) US12030937B2 (enExample)
EP (1) EP4225801A1 (enExample)
JP (1) JP7844430B2 (enExample)
CN (1) CN115884987A (enExample)
CA (1) CA3189562A1 (enExample)
IL (1) IL299894A (enExample)
WO (1) WO2022013819A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137676A (zh) * 2015-03-20 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) gp120中和抗体及其用途
CN110088133A (zh) * 2016-07-29 2019-08-02 朱诺治疗学股份有限公司 抗独特型抗体及相关方法
CN110462038A (zh) * 2017-02-07 2019-11-15 第一三共株式会社 抗gprc5d抗体和包含所述抗体的分子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137676A (zh) * 2015-03-20 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) gp120中和抗体及其用途
CN110088133A (zh) * 2016-07-29 2019-08-02 朱诺治疗学股份有限公司 抗独特型抗体及相关方法
CN110462038A (zh) * 2017-02-07 2019-11-15 第一三共株式会社 抗gprc5d抗体和包含所述抗体的分子

Also Published As

Publication number Publication date
IL299894A (en) 2023-03-01
CA3189562A1 (en) 2022-01-20
US12030937B2 (en) 2024-07-09
US20220064284A1 (en) 2022-03-03
WO2022013819A1 (en) 2022-01-20
EP4225801A1 (en) 2023-08-16
JP7844430B2 (ja) 2026-04-13
JP2023535684A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
TWI918704B (zh) Ｃｃｒ８抗體及其應用
JP7129449B2 (ja) ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
CN109988240B (zh) 抗gpc-3抗体及其用途
TW201439116A (zh) 抗－顆粒溶解素抗體及其應用
TW201811828A (zh) 抗原結合分子和使用彼之方法
CN118515779A (zh) 抗hk2嵌合抗原受体（car）
US12162951B2 (en) Anti-idiotypic antibodies against anti-KLK2 antibodies
JP7844430B2 (ja) 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体
US20230094867A1 (en) Anti-idiotypic antibodies against anti-cd79b antibodies
KR20120098809A (ko) 제2형 당뇨병용 마커 단백질
TW202436355A (zh) 抗原結合分子及使用方法
WO2025061149A1 (zh) 抗gcc抗体、嵌合抗原受体及其用途
HK40130350A (en) Antigen binding molecules and methods of use
AU2022246948A1 (en) Il-38-specific antibodies
CN120005021A (zh) 抗lag-3抗体及其用途
CN121914265A (zh) 一种抗胃泌素释放肽前体的抗体及其应用
TW202608921A (zh) 抗ｉｌ１ｒａｐ抗體以及其用途
BR112018067951B1 (pt) Anticorpo anti- transcrito 7 semelhante à imunoglobulina, composição farmacêutica e uso dos mesmos
BR122025022696A2 (pt) Anticorpo anti-transcrito 7 semelhante à imunoglobulina e seu método de produção

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination